Companies / Jasper Therapeutics Inc
Jasper Therapeutics Inc
Nasdaq: JSPRCIK 1788028REDWOOD CITY, CA
Financials
Ownership
28.0M shares outstanding · as of May 11, 2026
Ownership
| Institutions | 75.58% | 21,161,089 |
| Public float | 24.42% | 6,835,730 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 3
View all →| Insider | % of shares | Shares |
|---|---|---|
Cross HerbChief Financial Officer | — | — |
Mahal Jeetinder SinghCEOFormerCEO and President · Director | — | — |
Martell RonCEOFormerPresident, CEO and Director · Director | — | — |
Institutional holders 63
View all →| Holder | Value | % of shares |
|---|---|---|
| $4.88M | 9.53% | |
| $3.60M | 7.04% | |
| $3.27M | 6.38% | |
| $3.20M | 6.24% | |
| $2.43M | 4.74% | |
| $2.01M | 3.93% | |
| $1.90M | 3.72% | |
| $1.45M | 2.84% | |
| $1.42M | 5.78% | |
| $1.18M | 4.83% |
Activity
InsidersInstitutions
What insiders are doing in this stock (Form 4).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | Mahal Jeetinder Singh CEO | Grant | Stock Option (right to buy) | — | +500K | 500,000 1.79% of shares | low |
| Jan 2, 2026 | Martell Ron CEO | Grant | Stock Option (right to buy) | — | +234K | 234,000 0.84% of shares | low |
| Jan 2, 2026 | Mahal Jeetinder Singh CEO | Grant | Stock Option (right to buy) | — | +90K | 90,000 0.32% of shares | low |
| Jan 2, 2026 | Cross Herb Executive | Grant | Stock Option (right to buy) | — | +90K | 90,000 0.32% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Integrated Core Strategies (US) LLC | Passive13G | — |
| Acorn Bioventures, L.P. | Passive13G/A | — |
| Morgan Stanley | Passive13G | — |
| The Goldman Sachs Group, Inc. | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| JSPR | Common Stock | 471871202 |